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Mass spectrometry methods have been used to characterize two proteins: an opioid peptide- 
containing protein extracted from bovine pituitary, and bovine cl-lactalbumin (BAL). A 
protein that contains pendorphin was found in bovine pituitary, and that protein was 
characterized with electrospray ionization mass spectrometry (ESIMS), el permeation chro- 
matography, reversed-phase high performance liquid chromatography RP-HPLC), radioim- B 
munoassay, trypsinolysis, and liquid secondary ion mass spectrometry (LSIMS). 
BAL is a protein that was used as a model to develop analytical methods to study opioid 
peptide-containing proteins. Commercial BAL was purified by RP-HPLC, and its molecular 
weight (M.W.) was determined by ESIMS. The shift in mass observed following dithiothreitol 
(DTT) reduction estimated the number of disulfide bonds. 
For all of the data obtained for BAL with or without RP-HPLC separation, ESIMS 
determined the M.W. of the peptides produced by trypsin treatment of BAL, and LSIMS 
selected a precursor ion, the protonated molecule ion [M + HI*, of a tryptic peptide, which 
was analyzed by tandem mass spectrometry. Following MT reduction, ESIMS and LSIMS 
detected each peptide that contained disulfide bonds in that mixture of tryptic peptides. (J 
Am Sot Mass Spectrom 1994, 5, 377-386) 
e qualitative and quantitative analysis of neu- 
T ropeptides in biologic tissues and fluids is a main research activity for this laboratory [l-131, 
especially the endogenous opioid and tachykinin neu- 
ropeptidergic systems in human pituitary tissue. Mass 
spectrometry methods have been developed and used 
to optlmize the molecular specificity of those qualita- 
tive and quantitative analytical measurements. For ex- 
ample, tandem mass spectrometry (MS/MS) in the 
multiple reaction monitoring &TRM) mode has been 
used to quantify endogenous methionine enkephalin 
(ME) [5, 111 and findorphin (BE) [91 in human post- 
mortem control and postsurgical tumor pituitaries [6, 
71. We have also shown for the first time in the human 
trigeminal system, the presence of opioid peptide-con- 
taining proteins that lead to ME 1141. Recently, electro- 
spray ionization (ESI) has facilitated the analysis of 
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those opioid peptide-containing proteins [ 151, and will 
also be used to clarify neuropeptidergic systems in the 
pituitary. 
An opioid neuropeptide derives metabolically in the 
cell body of a neuron from a protein that contains 
approximately 260 amino acids 1161. For example, ME 
and BE are produced from two different proteins, 
preproenkephalin A (263 amino acids) and proopiome 
lanocortin (POMC) (265 amino acids), respectively, 
through one or more intermediate-sized opioid pep- 
tide-containing proteins (“intermediate-sized” means 
fewer than the - 260 amino acids in a precursor, but 
more than the 5 or 31 amino acids in ME or BE, 
respectively). The amino acid sequence of pre- 
proenkephalin A and of POMC was deduced by the 
use of recombinant DNA techniques [16]. However, 
the number and the characterization of intermediate- 
sized opioid peptide-containing proteins remain uncer- 
tain for the steps involved in the metabolism from 
preproenkephalin A to ME and from POMC to BE. 
During axonal transport, proenkephalin A and 
POMC are metabolized through one or more interme- 
diate-sized opioid peptide-containing proteins to pro- 
duce the neuropeptide, which is packaged in vesicles. 
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For ESIMS, the source accelerating voltage was 4 
kV, and the ES1 probe tip-to-counter electrode voltage 
was 3 kV. The samples were dissolved in a solvent of 
CHsOH:H,O (l:l, v:v> containing 1% CH,COOH; the 
BAL concentration was - 25 pmol/wl. An aliquot (20 
~1) of the sample solution was introduced into the ES1 
source at a flow-rate of 3 pl/min with a syringe pump 
(Harvard Model 22, Woburn, MA). 
For an ESIMS scan of a protein, typical MS-l instru- 
ment operating parameters were: mass resolution = 
-200; mass range = 100-2500; scan-rate = 5 s/de- 
cade; data acquisition time = 10 min; number of scans 
accumulated = - 100. Mass calibration was performed 
with the [M + 2H]‘+ ion of Gramicidin S at m/z 
571.4. All data were smoothed and transformed using 
the VG software. 
For LSIMS, Cs+ ions with an energy of 35 keV were 
used. The source accelerating voltage was 8 kV. Mass 
resolution was - 1200, and glycerol was used as the 
matrix. The spectra were obtained at a scan-rate of 5 
s/decade, and mass calibration was performed with 
CSI. 
The average mass value was used for the ESIMS 
data for the opioid peptide-containing protein and for 
intact BAL, and monoisotopic mass values were used 
for all LSIMS and all multiply charged ES1 ions. 
MS/MS 
For MS/MS, LSIMS was used for sample ionization, 
MS-1 selected the precursor ion, and MS-2 collected 
the product ion spectrum. MS-2 was operated at 5 
s/scan, and mass resolution was one (at m/z 500). 
Helium was used as the collision gas, and the helium 
pressure within the collision cell was adjusted to re- 
duce the precursor ion current by - 50%. 
Results and Discussion 
Bovine Pituitary Opioid Pepfide-Containing Protein 
GP and RP-HPLC separation of a bovine pituitary 
homogenate produced fractions that contained ME-li 
after treatment with trypsin and CNBr, and those 
fractions were analyzed by ESIMS to determine the 
M.W. of the protein. 
ESIMS analysis of one of those fractions showed the 
presence of three major components, with M.W. values 
of 6550, 8440, and 9855 Da, respectively. Figure 2a 
shows the ES1 mass spectrum, and Figure 2b the trans- 
formed ES1 mass spectrum of that fraction. Trypsin 
treatment of this mixture, when analyzed by LSIMS, 
showed the presence of ions at m/z 558 (I) and 
1134 (II) (among others) (Figure 3); those two ions 
correspond to BE,,_,,(= POMC,,,_,,,) and 
BE,,_,,( = POMC,,,.,,,), respectively [9]. Those two 
peaks of m/z 558 and 1134 were also present in the 
fast-atom bombardment (FAB) spectrum from the 
trypsin treatment of endogenous BE (M.W. 3465) in 
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Figure 2. ES1 mass spectrum of a fraction extracted from bovine 
pituitaries that contained ME-li. (a) ES1 mass spectrum; (b) trans 
formed ES1 mass spectrum. Ions associated with 9855 (+), 8440 
(A), and 6550 (0) are indicated. 
our previous studies [6]. Therefore, those LSIMS data 
indicate that this fraction contains a BE-containing 
protein. 
That fraction was subjected to further HPLC separa- 
tion and the component with a M.W. of 6550 was 
removed (data not shown). The component with a 
M.W. of 8440 was difficult to remove without a con- 
comitant and unavoidable loss of the component with 
a M.W. of 9855. The component with a M.W. of 8440 is 
not trypsin-sensitive because it remains in the ES1 
spectrum following trypsin treatment but 9855 disap- 
pears 
Therefore, the component with a M.W. of 9855 is the 
putative intermediate-sized precursor to BE in bovine 
pituitary. More pituitary sample is being accumulated; 
that fraction will be subjected to further HPLC separa- 
tion, and that putative BE-containing protein will be 
characterized by trypsin treatment, ESIMS, LSIMS, and 
MS/MS sequencing of each tryptic fragment. In that 
manner, that BE-containing protein with a M.W. of 
9855 will be located within POMC. That result will 
permit the elucidation of the metabolic processing of 
POMC. 
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Figure 3. LSlMS spectrum of the mixture of 
peptides produced by trypsin treatment of the 
fraction that contained ME-I. Note the ions at 
m/z 558 (I) and 1134 (II), which correspond to 
BE,_2, and BE,,_19, respectively. 
Bovine ol-Lactalbumin 
Scheme Ill contains the experimental protocol used for 
the study of BAL. Three separate experiments were 
conducted: I, M.W. determination; II, irypsin, no 
I-PLC; and III, trypsin, with HPLC. In experiment I, 
BAL was analyzed directly by ESIMS to determine the 
M.W. of the protein, and again after DTT reduction to 
provide the M.W. of reduced BAL. The number of 
disulfide bonds in BAL was estimated by the differ- 
ence in those two M.W. values. 
In experiment II, BAL was treated with trypsin, and 
the mixture of tryptic peptides was screened by mass 
spectrometry. ESIMS and LSIMS provided the M.W. of 
the majority of the tryptic peptides. Some of the more 
abundant tryptic peptides in the mixture were ana- 
lyzed further by LSIMS-MS/MS to obtain the amino 
acid sequence of the selected tryptic peptide. The mix- 
CI-LSIMS’HS,HS 
Scheme III. Experimental protocol used to anaIyze BAL by 
ESIMS, DTI reduction of d&&fide bonds, trypsin treatment, 
LSIMS, MS/Ms, and IWHPLC. 
ture of the DTT-reduced tryptic peptides was analyzed 
by ESIMS and LSIMS to detect those peptides that 
contain disulfide bonds. 
In experiment III, the mixture of tryptic peptides 
was separated by RI’-HPLC, which is used when a 
sufficient amount of a biological sample is available. 
ESIMS and LSlMSMS/MS analyzed the individual 
RP-HPLC-purified peptides. ESIMS, following DTI re- 
duction, was used to detect those peptides that contain 
disulfide bonds. 
Determination of the molecular weight, and fhe number of 
protonation sites, and An estimation of fhe number of disul- 
fide bonds in bovine a-lactalbumin. Molecular weight of 
BAL. Figure 4a contains the ES1 mass spectrum of 
BAL and Figure 4b the corresponding mass spectrum 
after D’lT reduction, The insets in Figure 4a and b 
contain the corresponding transformed ESIMS data. In 
Figure 4a, the observed ion species range from 7+ to 
12*, and in Figure 4b, from Et+ to 19+. The M.W. of 
BAL is determined to be 14,174 k 2 Da (n = 5); the 
calculated average M.W. is 14,175. The relative stan- 
dard deviation of the five determinations is +0.02%. 
Number of proton&ion sites. In BAL, the number 
of basic amino acid residues plus the N-terminus of 
the protein is 17. From Figure 4a, the maximum num- 
ber of charges observed in the ES1 spectrum is 12. As 
mentioned by other researchers 1201, during ESIMS 
several basic amino acids may remain buried within 
the structure of a folded protein such as BAL, and thus 
they would not be protonated. The folded structure is 
maintained by the four disulfide bonds in BAL. 
It is interesting to speculate on which one of the 
basic amino acids in BAL remains buried and thus 
resistant to protonation in the disulfide-folded struc- 
ture. The “Lys residue Gee Figure la) may be a 
candidate for such a buried residue because when 
trypsin (powder or beads) was used, that residue, 
which is located next to a disulfide bond, is incom- 
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Figure 4. ES1 mass spectrum of bovine a-lactalbumin before (a) 
and after (b) DTI’ reduction of disulfide bonds. The insets in each 
mass spectrum show the corresponding transformed ESIMS data. 
pletely hydrolyzed at its C-terminal bond (data not 
shown). 
DTT can be used to reduce the disulfide bonds in a 
protein and open the folded structure into a more 
linear structure, thus allowing the buried basic amino 
acids to become available for protonation. After DTT 
reduction (see Figure 4b), the ESIMS spectrum shows 
that the maximum number of charges increased by 7 
(from 12 to 19). That latter value approximates the 
number of amino acids that could be protonated in 
BAL (K = 12, R = 1, H = 3, plus the amino terminus). 
Protonation of the Gln side chains in BAL is also a 
possibility [201. Clearly, all of the basic amino acid 
residues of BAL have been protonated following DTT 
reduction of disulfide bonds using this present experi- 
mental protocol. Other researchers [20] have noted a 
mass shift following reduction, but the data in Figure 
4b show a higher level of disulfide bond reduction (a 
shift towards 19+ compared to the 16+, and a different 
intensity distribution, compared to the spectrum in 
Figure 4 in Ref. [20]) because nitrogen was used here 
during the reduction to minimize the reoxidation of 
DTT-reduced disulfide bonds. 
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Estimation of the number of disulfide bonds in 
BAL. The M.W. of DTT-reduced BAL is determined to 
be 14,183 +2 Da (n = 5); the RSD is +O.Ol%. The 
M.W. of BAL increases by nine mass units following 
D’I”T reduction (Figure 4b versus 4a). That increase in 
mass correlates to the total number of disulfide bonds 
in BAL (9/2 = 4.5; truncate to 4 f 2). Similar data (not 
presented here) were obtained for the corresponding 
ESIMS analysis (with and without DTT) of lysozyme. 
However, that difference in mass (Figure 4a versus 
4b, transformed data) must be interpreted carefully. 
For example, for an unknown protein that contains 
disulfide bonds, several experimental parameters must 
be optimized to more accurately calculate the number 
of disulfidc bonds: instrumental resolution, mass cali- 
bration, maximum amount of sample to provide an 
optimal number of scans, and optimal number of 
[M + nH]“+ peaks in an ES1 mass spectrum. 
During a study of opioid peptide-containing pro- 
teins in the bovine pituitary [15], this method was 
used to determine whether chromatographic fractions 
contained proteins with disulfide bonds (no disulfide 
bonds were found). 
Analysis of tryptic peptides. No RF-HPLC separation. 
Figure lb contains a list of all the tryptic peptides that 
could be produced by trypsin treatment of BAL, their 
amino acid sequence, and their M.W. as monoisotopic 
mass values. The mixture of tryptic peptides was ana- 
lyzed directly by LSIMS and ES1 without any HPLC 
separation, and those data are collected in Table 1. This. 
type of experiment on a mixture of tryptic peptides is 
useful as a very effective initial screen during some 
experiments (see Figure 3). 
Figure 5 (the LSIMS spectrum of the mixture), con- 
tains [M + HI+ ions that correspond to the tryptic 
peptides with M.W. values of 374, 388, 487, 617, 1200, 
and 1684 (very weak). 
Similarly, the ES1 mass spectrum shown in Figure 6 
of the mixture of tryptic peptides contains [M + r&I]*’ 
Table 1. Peptides produced by trypsin trcahnent of BAL and 
analyzed with LSIMS and ES1 (no Dl-F reduction); 
with and without RP-HPLC separation 
No HPLC HPLC 
M.W. LSIMS ESI ESI 
374 + + 
388 + t : 
487 + + + 
617 + f t 
1200 + + + 
1684 + t + 
4071 - + + 
5301 _ - + 
Plus= found; minus= not faund: all masses are monoisotOpiC. 
rounded off to the nearest nteger H) See text The appropriate 
protonated molecule ions of these fwo peptides were found m the 
mixture of unresolved components that eluted within the HPLC 
s01Ve”f front. 
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Figure 5. ISIMS spectrum of the mixhue of peptides produced 
by trypsin treatment of bovine u-lactalbumin. Pertinent peptides 
discussed in the text are indicated by arrows in this spectrum, 
and are listed in Table 1. 
ions that correspond to the hyptic peptides with M.W. 
values of 374 [375 (1 +)I, 388 [389 (1 +>I, 487 [488 (1 +I, 
244 (2 +)I, 617 [309 (2 +>, very small, unlabeledl, 1200 
[601 (2 +I], 1684 [843 (2 +>, 562 (3 +)I, and 4071 [NJ19 
(4 +), 815 (5 +)I. It is interesting to note that the largest 
disulfide-containing tryptic peptide with a M.W. of 
5301 is missing in the ES1 mass spectrum of the mix- 
ture contained in Figure 6. It is possible that ES1 is not 
an effective mode for the analysis of this particular 
peptide in this mixture because of the small number 
(4) of charge sites compared to its large number (48) of 
ammo acids. 
The LSIMS product-ion spectra of selected tryptic 
peptides in the mixture produced by trypsin treatment 
of BAL (Scheme III, experiment IIB) were obtained. 
For example, note in Figure 5 the abundant [M + HI+ 
ion at m/z 488. Figure 7 contains the corresponding 
Figure 6. ES1 mass spectrum of the mixture of peptides prcr 
duced by trypsin treatment of bovine a-lactalbumin. Pertinent 
peptides discussed in the text are indicated by arrows in this 
spectrum, and are listed in Table 1; (A) ions associated with the 
peptide with a M. W. of 4071, (0) 1684, and ( l ) 487. 
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Figure 7. LSIMStandem mass spectrum of the precursor ion 
m/z 488. That precursor ion is also shown in the LSIMS spectrum 
of tryptic peptides in Figure 5. Amino acid sequence-determining 
ions are indicated. 
product-ion spectrum of that 488 ion, and contains 
amino acid sequence-determining fragment ions at 
m/z 375 (y,, loss of Ile/Leu), 262 (y2, loss of Leu/Ile), 
and 147 (y?, loss of Asp). Also, that 488 ion is the 
precursor for 342 (bs, loss of Lys) and 227 (b,, loss of 
Asp). 
Two other precursor ions (m/z 375 and 389) shown 
in Figure 5 were analyzed in that mixture by MS/MS, 
and excellent product-ion spectra were obtained (data 
not shown). The [M + HI+ ion at m/z 375 is the 
precursor for 260 (y2, loss of Asp), 147 (yl, loss of 
Leu/Ile), and 229 cbbl, loss of Lys). The other [M + H]+ 
ion at m/z 389 is the precursor for 260 (y2, loss of Glu) 
and 147 (y,, loss of Leu/Ile). 
DTT reduction of disulfide bonds of the tryptic 
peptides was performed (Scheme III, Experiment UC), 
and the corresponding LSIMS and ES1 mass spectra are 
shown in Figures 8 and 9, respectively. As demon- 
strated by the data in Figure lb, the disulfide-bond 
Figure 8. LSIMS spectrum of the mixture of peptides produced 
by hypsin treatment of bovine or-lactalbumin, foollowed by m 
reduction. Pertinent peptides discussed in the text are indicated 
by arrows and are listed in Table 2. 
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Figure 9. ES1 mass spectrum of the mixture of pcptidcs pro- 
duced by trypsin treatment of bovine a-lactalbumin, followed by 
DTT reduction. Pertinent peptides discussed in the text are 
indicated by arrows, and are Listed in Table 2. 
containing tryptic peptides with M.W. values of 1684, 
4071, and 5303 are pertinent. The peptide at 1684 after 
DTI reduction produces two peptides with M.W. val- 
ues of 652 and 1033 (see Table 2); 4071 produces three 
peptides with M.W. values of 548,1638, and 1889; and 
5301 produces two peptides with M.W. values of 649 
and 4654. In the LSIMS spectrum (Figure 8), the ion at 
m/z 1034 corresponds to the peptide of M.W. 1033 in 
Table 2 and indicates the presence of the peptide with 
a M.W. of 1684; m/z 650 indicates 5301; and m/z 549 
indicates 4071. 
Similarly, the ES1 mass spectra (Figure 9) of that 
mixture indicates a peptide with a M.W. of 1684 by the 
peptides with ions at 1033 [518 (2+)1; 5301 by 4654 
[ 1551 (3 +) in another ES1 mass spectrum, not shown] 
and 649 [325 (2 +)I; and 4071 by 1638 [820 (2 +)I, 1889 
[631 (3 +)], and 548 [275 (2 +)I. 
RP-HPLC separation. Mass spectrometcy data fol- 
lowing RP-HPLC separation were obtained for the set 
of peptides produced by trypsin treatment of BAL 
(Scheme III, experiment III). Selected specific examples 
Table 2. Peptides produced by trypsin treatment of BAL and 
analyzed after Dl’T reduction with LSIMS and ES1 
(with and without RP-HPLC separation) 
Reduction No HPLC HPLC 
Before After LSIMS ESI ESI 
1664 652 _ + 
1033 + + + 
4071 549 + + + 
1638 _ + + 
1899 - + + 
5301 649 + i- + 
4654 _ + - 
Plus=found, minus= not found: all masses are monoisatopic, 
rounded off to the nearest integer. 
Figure 10. ES1 mass spectra of HPLC-separated peptides prs 
duced by trypsin treatment of bovine or-lactalbumin. (a) Pcptide 
with a M. W. of 4071 [lo19 (4+), 815 (S-t)]; (b) Peptidc with a M. 
W. of 1684 1843 (2 +), 562 (3 +), 422 (4 +)I. 
will demonstrate the data listed in the Table 1 HPLC 
column. ES1 mass spectra were obtained for the sepa- 
rated peptides with M.W. values of 487, 617, 1200, 
1684, 4071, and 5301. (The peptides with M.W. values 
of 374 and 388 were eluted unresolved in the HPLC 
solvent front. The ES1 mass spectrum (not shown) of 
that solvent front contained a mixture, in which 375+ 
and 389+ were observed.) In addition, an ES1 mass 
spectrum (not shown) was obtained for a peptide with 
a M.W. of 1797, which corresponds to the peptide at 
1684 plus Leu; that peptide derives from 9% incom- 
plete trypsinolysis of the C-terminal lzK - L bond 
(see Figure la). 
Figure 10a contains the ES1 mass spectrum of the 
tryptic peptide with a M.W. of 4071, and shows the 
presence of ions at m/z 1019 (4+) and 815 (5 +>. 
Similarly, Figure 10b contains the data for the peptide 
with a M.W. of 1684, and shows ions at m/z 843 (2 i-1, 
562 (3 +), and 422 (4 t). 
In Scheme III, experiment IIIB, BAL was treated 
with trypsin, and the mixture of tryptic peptides was 
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Figure 11. ES1 mass spectrum of the HPLC-separated tryptic 
peptide with a M. W. of 1684, followed by DTT treatment to 
produce peptides with M. W. vahes of 652 (0). 653 cl+), 327 
(2 +); and 1033 ( .) 1034 cl+), 518 (2+). 
separated by RI’-HPLC. Those tryptic peptides that 
contain disulfide bonds were treated with DTT and 
analyzed by ESIMS. As shown by the fragments listed 
in Figure lb and indicated in Table 2 by the products 
expected after DTI reduction, peptides with M.W. 
values of 652 and 1033 should be produced from the 
1684 peptide. The ES1 mass spectrum shown in Figure 
11 contains ions that correspond to a peptide with a 
M.W. of IO33 [lo34 (1 +), 518 (2 +:)I, and the ions 1653 
(l+), 327 (2 +)] indicate the presence of the peptide 
with a M.W. of 652. These two DTT-reduced peptides 
(652, 1033) indicate the peptide with a M.W. of 1684. 
The data in Figure 12 are the corresponding data for 
the tryptic peptide with a M.W. of 4071, which had 
been reduced by DTT to produce three peptides with 
M.W. values of 548, 1638, and 1889. The presence of 
the peptide with a M.W. of 548 is substantiated by the 
peaks at m/z 549 (1 +) and 275 (2 +I, the peptide at 
1889 by m/z 946 (2 +> and 631 (3 +), and the peptide 
at 1638 by m/z 820 (2 +>. 
The tryptic peptide with a M.W. of 5301, following 
D’IT treatment, is substantiated by the peak at m/z 
649 [325 (2 +)I (data not shown). 
Finally, data from experiment IIIC are shown in 
Figure 13, which contains the LSIMStandem mass 
spectrum of the HPLC-purified tryptic peptide with a 
M.W. of 617 (see Table 1). Amino acid sequence- 
determining fragment ions in this product-ion spec- 
trum are seen at m/z 489 (y,, loss of Glu), 361 (ys, loss 
of Gin), 248 (yZ, loss of Leu/Ile), and 147 (yl, loss of 
Thr), and ions from the b-series at 258 (b2, loss of 
Thr-Lys) and 371 (bs, loss of Leu-Thr-Lys). 
Interestingly, many peptides are found without any 
RI’-HPLC separation by either ESIMS or LSIMS (Table 
1); only the very large tryptic peptide with a M.W. of 
5301 was not found without BP-HPLC separation (see 
discussion above). However, all tryptic peptides, in- 
cluding the peptide with a M.W. of 5301, were found 
Figure 12. ES1 mass spectrum of the HPLCseparated tryptic 
peptide with a M. W. of 4071, followed by DlT treatment to 
produce peptides with M. W. values of 1638 (+) 820 (2 +); 1889 
(a) 946 (‘2 +I, 631 (3 +I; and 548 (A 1549 (1 +I, 275 (2 +)I. 
when HPLC separation preceded mass spectrometry 
analysis. In general, ESIhJS provided more data than 
LSIMS. Thus, trypsinolysis works fine on BAL before 
any disulfide bond reduction with DTT. 
Conclusions 
A BE-containing protein extracted from bovine pit- 
uitary and a commercially available protein can be 
characterized by a combination of mass spectrometry 
methods. For example, ESIMS indicates that the M.W. 
of the BE-containing protein is 9855 Da. Further, LSIMS 
of the mixture of peptides produced by trypsin treat- 
ment of that protein shows the presence of two unique 
tryptic peptides (M.W. values of 557 and 1133). The 
amino acid sequence of those tryptic peptides, and 
Figure 13. LSIMStandem mass spectrum of the HPLC-purified 
hyptic peptide with a M. W. of 617. Amino acid sequence 
determining fragment ions of the y-series and b-series are imii- 
cated. 
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thus of the 9855 protein, is currently being determined, 
and those data will locate that BE-contain@ protein 
within POMC. 
BAL has served well as a model protein for these 
studies. BAL has been analyzed by ESIMS, DTT reduc- 
tion of disulfide bonds, trypsin treatment, RI’-HPLC 
separation, LSIMS, and MS/MS. This study was per- 
formed because a model compound was required for 
the method development for the separation and analy- 
sis of opioid peptide-containing proteins obtained from 
the pituitary (Refs. [14,15]; Fridland, G. and Desiderio, 
D. M., Analyt. Lett., submitted). 
ESIMS was used to determine the M.W. of HPLC- 
purified BAL, and trypsin treatment to produce a mix- 
ture of peptides that is analyzed (with and without 
RF’-HPLC) by ESIMS, LSIMS, and MS/MS of selected 
precursor ions in the LSIMS spectrum of the mixture of 
tryptic peptides. DTT was used to reduce disulfide 
bonds in BAL and the tryptic peptides. 
This study illustrated several important experimen- 
tal features that are applicable to the analysis of 
proteins in general, and to opioid peptide-containing 
proteins and BAL in particular: one peptide bond 
(62Kp63N) in BAL is relatively difficult to hydrolyze 
with trypsin; DTT reduction of disulfide bonds is im- 
portant to uncover hidden basic amino acid residues; 
and it is important to avoid any reoxidation of a 
DTT-reduced protein. 
The study of BAL is important for analyzing opioid 
peptide-containing proteins. The characterization of 
each opioid peptide-containing protein and their place- 
ment within POMC will be used to clarify the metabolic 
processing of that opioid neuropeptidergic system. 
Then, a comparison of that processing will be made 
between control pituitaries and postsurgical pituitaries 
(especially neuroendocrinologically silent tumors) to 
help clarify those mechanisms that contribute to tumor 
formation in the human anterior pituitary. 
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